{
  "ticker": "LLY",
  "target_date": "2025-06-03",
  "actual_date": "2025-06-03",
  "collected_at": "2025-12-08T11:50:39.676365",
  "price": {
    "open": 743.52,
    "high": 754.23,
    "low": 738.75,
    "close": 748.0360107421875,
    "volume": 3056500,
    "change_1d_pct": 0.49,
    "change_7d_pct": 4.97,
    "change_30d_pct": -8.03
  },
  "technicals": {
    "rsi_14": 51.88,
    "sma_20": 736.91,
    "sma_50": 776.57,
    "macd": -16.007,
    "macd_signal": -19.708,
    "macd_histogram": 3.7,
    "bb_upper": 774.3,
    "bb_lower": 699.52,
    "price_vs_sma20_pct": 1.51,
    "price_vs_sma50_pct": -3.67,
    "volume_ratio": 0.67
  },
  "fundamentals": {
    "market_cap": 891194703872,
    "pe_ratio": 48.707993,
    "forward_pe": 43.871586,
    "price_to_book": 37.4296,
    "price_to_sales": 14.998279,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.6,
    "pct_from_52w_low": 59.37
  },
  "macro": {
    "spy": {
      "price": 592.69,
      "change_1d_pct": 0.57,
      "change_7d_pct": 2.93
    },
    "vix": {
      "level": 17.69,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.46
    },
    "dollar_index": {
      "level": 99.25
    },
    "gold": {
      "price": 3350.2
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Eli Lilly (NYSE:LLY) Advances Ovarian Cancer Treatment And Transfers Cialis Rights In Latin America",
      "source": "Yahoo",
      "datetime": 1748972501,
      "summary": "Eli Lilly (NYSE:LLY) recently announced promising Phase 1 data for its folate receptor alpha antibody-drug conjugate, showcasing significant progress in oncology treatments for ovarian cancer. Additionally, the acquisition of Cialis rights in Latin America by Gr\u00fcnenthal highlights a strategic shift ",
      "url": "https://finnhub.io/api/news?id=f1b65073a9035df6c82465d384e14db25f82539f648a12f9d6cd169e6e5170ce"
    },
    {
      "headline": "Top 50 High-Quality Dividend Stocks For June 2025",
      "source": "SeekingAlpha",
      "datetime": 1748955192,
      "summary": "Track 50 top dividend growth stocks with daily valuation updates. Discover upgrades like Ferrari & Accenture, outperforming SPY & SCHD in 2023.",
      "url": "https://finnhub.io/api/news?id=019d2eb701e479ef25b7438df3bdf4961a9d2ab247e89a75ca9759239fdf6f7e"
    },
    {
      "headline": "Eli Lilly: encouraging results in ovarian cancer",
      "source": "Finnhub",
      "datetime": 1748939711,
      "summary": "Eli Lilly announces promising Phase 1 data for its antibody-drug conjugate targeting the alpha folate receptor , LY4170156, in platinum-resistant ovarian cancer. In heavily pretreated patients,...",
      "url": "https://finnhub.io/api/news?id=d405b2678b3e2fd95d30aab08d7cef2423bf7d05e74b2850d0c2a2973d55446f"
    },
    {
      "headline": "Exclusive-Wegovy use up 50% among US teens",
      "source": "Finnhub",
      "datetime": 1748930475,
      "summary": "LOS ANGELES -American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with...",
      "url": "https://finnhub.io/api/news?id=8d5d74d3e7294bf561d22a6f0fefd4337174639b19cc296966dcbef0442dd643"
    },
    {
      "headline": "S&P 500 Jumps 6.2% In May To Log Best Month Since 2023",
      "source": "SeekingAlpha",
      "datetime": 1748929140,
      "summary": "US stocks broadly jumped in May, with the S&P 500 registering its best month in over a year.",
      "url": "https://finnhub.io/api/news?id=a87240eac9e4b5631212549d6a8180fb3c398d5bc6b3143c67d4a7e62c2fce33"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-27",
      "description": "xslF345X05/wk-form4_1748376794.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000156/xslF345X05/wk-form4_1748376794.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772733.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000154/xslF345X05/wk-form4_1747772733.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772668.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000152/xslF345X05/wk-form4_1747772668.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772589.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000150/xslF345X05/wk-form4_1747772589.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772518.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000148/xslF345X05/wk-form4_1747772518.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}